These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19119291)

  • 1. [High-cost medicine--do we lack open and legitimate procedures for prioritising?].
    Johansson KA; Miljeteig I; Norheim OF
    Tidsskr Nor Laegeforen; 2009 Jan; 129(1):17-20. PubMed ID: 19119291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationing cancer treatment: a qualitative study of perceptions of legitimate limit-setting.
    Feiring E; Wang H
    BMC Health Serv Res; 2018 May; 18(1):342. PubMed ID: 29743065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taking decisions on expenditure for high-cost drugs at the regional level: a model for evaluating the overall impact of Trastuzumab in the Veneto Region of Italy.
    Buja A; Perissinotto E; Compostella A; Tramarin A; Rebba V; Pastorelli D; Grigoletto F; Gallo C; Rausa G; Gregori D
    J Eval Clin Pract; 2011 Apr; 17(2):298-303. PubMed ID: 20874838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priority setting and cardiac surgery: a qualitative case study.
    Walton NA; Martin DK; Peter EH; Pringle DM; Singer PA
    Health Policy; 2007 Mar; 80(3):444-58. PubMed ID: 16757057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priority-setting decisions for new cancer drugs: a qualitative case study.
    Martin DK; Pater JL; Singer PA
    Lancet; 2001 Nov; 358(9294):1676-81. PubMed ID: 11728542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priority setting at the micro-, meso- and macro-levels in Canada, Norway and Uganda.
    Kapiriri L; Norheim OF; Martin DK
    Health Policy; 2007 Jun; 82(1):78-94. PubMed ID: 17034898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priority setting in a hospital critical care unit: qualitative case study.
    Mielke J; Martin DK; Singer PA
    Crit Care Med; 2003 Dec; 31(12):2764-8. PubMed ID: 14668612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fairness and accountability for reasonableness. Do the views of priority setting decision makers differ across health systems and levels of decision making?
    Kapiriri L; Norheim OF; Martin DK
    Soc Sci Med; 2009 Feb; 68(4):766-73. PubMed ID: 19070414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan.
    Kondo M; Toi M
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):197-204. PubMed ID: 16445372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding.
    Sinclair S; Hagen NA; Chambers C; Manns B; Simon A; Browman GP
    Health Policy; 2008 May; 86(2-3):381-90. PubMed ID: 18243395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priority setting in kidney transplantation: a qualitative study evaluating Swedish practices.
    Omar F; Tinghög G; Carlsson P; Omnell-Persson M; Welin S
    Scand J Public Health; 2013 Mar; 41(2):206-15. PubMed ID: 23287398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
    Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
    Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond accountability for reasonableness.
    Friedman A
    Bioethics; 2008 Feb; 22(2):101-12. PubMed ID: 18251770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
    Rosevear M
    N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
    Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.